Roivant Sciences (ROIV) Price & Analysis

Compare

655 Followers

ROIV Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.73 - $13.06

Previous CloseN/A

Volume1.46M

Average Volume (3M)4.43M

Market Cap

$8.09B

Enterprise Value$3.73B

Total Cash (Recent Filing)$4.50B

Total Debt (Recent Filing)$99.69M

Price to Earnings (P/E)1.9

Beta0.95

Next Earnings

Nov 17, 2025

EPS Estimate

-0.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.25

Shares Outstanding682,881,700

10 Day Avg. Volume4,679,149

30 Day Avg. Volume4,434,999

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.46

Enterprise Value/Revenue160.61

Enterprise Value/Gross Profit177.70

Enterprise Value/Ebitda-3.80

Forecast

1Y Price Target

$15.64

Price Target Upside30.44% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentBrepocitinib is nicely positioned as an oral therapy to be used ahead of biologics and cell therapy, even if those potentially offer improved efficacy.

Financial PerformanceROIV ended the quarter with $4.5B in consolidated cash, cash equivalents, restricted cash, and marketable securities.

Share Repurchase ProgramThe company completed its $1.5B share repurchase program, reducing outstanding shares by over 15% since March 31, 2024.

Bears Say

Clinical Trial RisksThe trial carries some risks due to the lack of randomized experience with brepocitinib in the indication.

CompetitionThere is increasing competition in Graves' disease and thyroid eye disease, with novel therapies being developed by other companies.

Roivant Sciences News

3 Stocks to Buy Now, According to the Technical Analysis

As markets remain shaky, technical analysis helps investors find good stock opportunities. Using TipRanks’ Technical Analysis Screener, we...

7d ago

CXW

ACLX

Roivant Sciences reports Q1 EPS (33c), consensus (23c)

Reports Q1 revenue $2.17M, consensus $6.92M. “I am proud of our continued execution in this quarter, including clinical...

18d ago

ROIV

Roivant Sciences Earnings Call: Progress Amid Challenges

Roivant Sciences Ltd. (($ROIV)) has held its Q1 earnings call. Read on for the main highlights of the...

16d ago

ROIV

Promising Potential of Roivant Sciences’ Brepocitinib and Pipeline Fuels Buy Rating

Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Roivant Sciences and keeping the price target...

17d ago

ROIV

Roivant Sciences Reports Q1 2025 Financial Results

Roivant Sciences Ltd. ( ($ROIV) ) has released its Q1 earnings. Here is a breakdown of the information...

17d ago

ROIV

Is ROIV a Buy, Before Earnings?

Roivant Sciences Ltd. (ROIV) is scheduled to report 1st quarter earnings on 08/11/2025, before the market opens. Regarding...

20d ago

ROIV

Roivant Sciences placed on ‘Positive Catalyst Watch’ at JPMorgan

JPMorgan analyst Brian Cheng placed Roivant Sciences (ROIV) on “Positive Catalyst Watch” while keeping an Overweight rating on...

1M ago

ROIV

Roivant Sciences resumed with a Buy at Goldman Sachs

Goldman Sachs resumed coverage of Roivant Sciences (ROIV) with a Buy rating and $19 price target The firm...

2M ago

ROIV

Roivant Sciences participates in a conference call with JPMorgan

JPMorgan previews Brepocitinib’s upcoming dermatomyositis readout in 2H on a conference call to be held on June 25...

2M ago

ROIV

Roivant Sciences Announces $500M Share Repurchase Program

An announcement from Roivant Sciences ( ($ROIV) ) is now available. Roivant Sciences Ltd. has announced a new...

2M ago

ROIV

Roivant Sciences announces $500M share repurchase program

In a regulatory filing, the company stated, “On June 24, 2025, the board of directors of Roivant Sciences...

2M ago

ROIV

Optimistic Outlook for Roivant Sciences: Buy Rating Backed by Brepo’s Potential and Financial Opportunities

J.P. Morgan analyst Brian Cheng has maintained their bullish stance on ROIV stock, giving a Buy rating on...

2M ago

ROIV

Optimistic Outlook for Roivant Sciences Driven by Promising Brepocitinib Results in Phase 3 VALOR Study

Leerink Partners analyst David Risinger has maintained their bullish stance on ROIV stock, giving a Buy rating yesterday....

2M ago

ROIV

Roivant Sciences’ Growth Potential Highlighted by Upcoming Phase 3 VALOR Study for Brepocitinib

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Roivant Sciences (ROIV...

2M ago

ROIV

ROIV FAQ

What was Roivant Sciences’s price range in the past 12 months?

Roivant Sciences lowest stock price was $8.73 and its highest was $13.05 in the past 12 months.

What is Roivant Sciences’s market cap?

Roivant Sciences’s market cap is $8.09B.

When is Roivant Sciences’s upcoming earnings report date?

Roivant Sciences’s upcoming earnings report date is Nov 17, 2025 which is in 80 days.

How were Roivant Sciences’s earnings last quarter?

Roivant Sciences released its earnings results on Aug 11, 2025. The company reported -$0.252 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.002.

Is Roivant Sciences overvalued?

According to Wall Street analysts Roivant Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Roivant Sciences pay dividends?

Roivant Sciences does not currently pay dividends.

What is Roivant Sciences’s EPS estimate?

Roivant Sciences’s EPS estimate is -0.31.

How many shares outstanding does Roivant Sciences have?

Roivant Sciences has 682,881,700 shares outstanding.

What happened to Roivant Sciences’s price movement after its last earnings report?

Roivant Sciences reported an EPS of -$0.252 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went down -2.785%.

Which hedge fund is a major shareholder of Roivant Sciences?

Currently, no hedge funds are holding shares in ROIV

Roivant Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-15.84%

Trailing 12-Months

Asset Growth

-22.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Roivant Sciences

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences (ROIV) Earnings & Revenues

Historic Earnings Reports

ROIV Company Deck

ROIV Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive overall sentiment with significant progress in the pipeline, particularly with the upcoming brepocitinib data, a strong financial position, and strategic share repurchase programs. However, challenges remain with ongoing LNP litigation and complexities in clinical trial management.View all ROIV earnings summaries

ROIV Stock 12 Month Forecast

Average Price Target

$15.64

▲(30.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","11":"$11","14":"$14","17":"$17","20":"$20"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,11,14,17,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.31,11.901538461538461,12.493076923076924,13.084615384615384,13.676153846153847,14.267692307692307,14.85923076923077,15.45076923076923,16.04230769230769,16.633846153846154,17.225384615384616,17.816923076923075,18.408461538461538,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.31,11.643076923076924,11.976153846153847,12.30923076923077,12.642307692307693,12.975384615384616,13.30846153846154,13.641538461538463,13.974615384615385,14.307692307692308,14.640769230769232,14.973846153846154,15.306923076923077,{"y":15.64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.31,11.324615384615385,11.33923076923077,11.353846153846154,11.368461538461538,11.383076923076924,11.397692307692308,11.412307692307692,11.426923076923076,11.441538461538462,11.456153846153846,11.47076923076923,11.485384615384616,{"y":11.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.83,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >